Cardiac amyloidosis was once considered a fatal diagnosis. New FDA-approved medications are now helping patients live longer. Here’s what doctors say about symptoms, treatment and early detection.

Cardiac amyloidosis is underrecognized in patients with heart failure; however, recent improvements in the understanding of this disease have led to developments in diagnosis and treatment. Cardiac ...

New drugs approved by the FDA are prolonging the lives of those affected.

Amyloidosis is a complex disease and the program at Huntsman Cancer Institute (HCI) uses a collaborative approach to provide comprehensive medical care. Researchers are tirelessly trying to find new ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) approved ...

Please provide your email address to receive an email when new articles are posted on . While currently there is no cure for systemic amyloidosis, treatment options have recently expanded and have led ...

Medically reviewed by Christopher Lee, MD Key Takeaways ATTR-CM often requires a team of healthcare providers, including cardiologists, specialists, and primary care doctors.Caregivers play an ...

Interviewer: Amyloidosis is a rare and possibly debilitating disease, which affects about 4,000 people a year in the United States. If left untreated, the disease can cause severe organ damage, so ...

H.C. Wainwright analyst Andrew Fein has maintained their bullish stance on PRTA stock, giving a Buy rating today. Andrew Fein’s Buy rating for Prothena’s stock is based on the promising potential of ...

Cardiac amyloidosis, or "stiff heart syndrome," is a rare manifestation of amyloidosis, which carries the worst prognosis of any involved organ. Researchers have developed a new technique that they ...

4,000 cases of AL Amyloidosis are reported each year in the United States. If you or someone you loved has been diagnosed with Amyloidosis, you may wonder what's the cause and how it gets cured.

Owing to the low incidence of AL amyloidosis, large studies are scarce and hardly any randomized, controlled studies comparing different therapeutic regimens have been conducted. Comparison of studies ...